

issues of data harmonization and linkage.

2. *Using RWD as part of the scientific paradigm, including open science, scientific rigor and reproducibility, and team science.* NIH seeks broad input on the opportunities and challenges related to using RWD as part of the scientific process.

(a) Approaches or methods for using RWD in collaborative teams and ensuring reproducibility.

(b) How do researchers assess the validation and verification of RWD data that is used in research.

(c) Appropriate open science practices and use of the FAIR principles (<https://www.nature.com/articles/sdata201618>) for research using RWD and approaches for maximizing appropriate data sharing when expected by the NIH Policy for Data Management and Sharing (<https://sharing.nih.gov/data-management-and-sharing-policy>) or other policies.

3. *Administrative and logistical considerations for collecting, using, and sharing RWD for biomedical and behavioral research.* NIH seeks broad input on the opportunities and challenges related to the process of acquiring, using, and making RWD available for biomedical and behavioral research, including:

(a) Pros and cons of various approaches for obtaining RWD through algorithms, purchasing RWD through trusted parties, accessing RWD through secure enclaves, etc.

(b) Considerations regarding licensing, costs, third party involvement, and restrictions for data use and sharing.

(c) Availability/utility of emerging de-identification technologies and data storage/sharing considerations.

4. *Ethical considerations for using RWD for biomedical and behavioral research.* NIH seeks broad input on the opportunities and challenges related to potential bioethical issues regarding the collection, use, and sharing of RWD, including:

(a) Strategies for protecting participant privacy and autonomy.

(b) Potential re-identification risks for RWD, including the technical feasibility of re-identifying linked data and the possibility of anonymity for patients, research participants, and their families.

(c) Ethical implications of data as a “commodity”, in terms of buying and selling personal health data.

This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States Government. The Government will not pay for the preparation of any

information submitted or for the Government’s use. Additionally, the Government cannot guarantee the confidentiality of the information provided.

Dated: September 21, 2023.

**Tara A. Schwetz,**

*Acting Principal Deputy Director, National Institutes of Health.*

[FR Doc. 2023–21239 Filed 9–27–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Establishment of the Social and Community Influences on Health Integrated Review Group

Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. 1001–1014), the Director, National Institutes of Health (NIH) announces the establishment of the Social and Community Influences on Health Integrated Review Group (IRG) as authorized by 42 U.S.C. 282(b)(16), section 402(b)(16) of the Public Health Service Act, as amended.

The Director, NIH, has determined that the Social and Community Influences on Health IRG is in the public interest in connection with the performance of duties imposed on NIH by law, and that these duties can best be performed through the advice and counsel of the committee.

The committee provides advice and recommendations on funding applications and proposals, including but not limited to, the scientific and technical merit of applications for grants-in-aid for research, research training, or research-related grants and cooperative agreements, or contract proposals relating to scientific areas relevant to social, interpersonal, community, and cultural influences on health, development, and well-being across the life span.

Inquiries may be directed to Claire Harris, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496–2123, or [Claire.Harris@nih.gov](mailto:Claire.Harris@nih.gov).

Dated: September 21, 2023.

**Lawrence A. Tabak,**

*Acting NIH Director, National Institutes of Health.*

[FR Doc. 2023–21234 Filed 9–27–23; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Cancer Institute.

This meeting will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below with attendance limited to space available. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session can be accessed from the NIH Videocast at the following link: <http://videocast.nih.gov/>.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, National Cancer Institute.

*Date:* November 13, 2023.

*Open:* 10:00 a.m. to 10:30 a.m.

*Agenda:* Remarks from the NCI Director.

*Closed:* 10:30 a.m. to 4:00 p.m.

*Agenda:* Personnel qualifications and performance, and competence of individual investigators.

*Name of Committee:* Board of Scientific Counselors, National Cancer Institute.

*Date:* November 14, 2023.

*Closed:* 11:00 a.m. to 1:45 p.m.

*Agenda:* Personnel qualifications and performance, and competence of individual investigators.

*Place:* National Institute of Health, Building 31, C Wing, 6th Floor, Conference Room C, 9000 Rockville Pike, Bethesda, MD 20892 (Hybrid Meeting).

*Contact Person:* Brian E. Wojcik, Ph.D., Senior Review Administrator, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W414, Rockville, MD 20850, 240–276–5660, [wojcikb@mail.nih.gov](mailto:wojcikb@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when